{"id":655133,"date":"2023-06-12T13:08:01","date_gmt":"2023-06-12T13:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655133"},"modified":"2023-06-12T13:08:01","modified_gmt":"2023-06-12T13:08:01","slug":"botulism-pipeline-clinical-trials-and-key-companiescompanies-xoma-cytodel-alphavax-panthera-biopharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/botulism-pipeline-clinical-trials-and-key-companiescompanies-xoma-cytodel-alphavax-panthera-biopharma_655133.html","title":{"rendered":"Botulism Pipeline, Clinical Trials, and Key Companies|Companies &#8211; XOMA, CytoDel, AlphaVax, PanThera Biopharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Botulism Pipeline, Clinical Trials, and Key Companies|Companies - XOMA, CytoDel, AlphaVax, PanThera Biopharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Botulism Pipeline, Clinical Trials, and Key Companies|Companies - XOMA, CytoDel, AlphaVax, PanThera Biopharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(United States, Nevada, Las Vegas), DelveInsight\u2019s\u201cBotulism &#8211; Pipeline Insight, 2023\u201d report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Botulism pipeline landscape.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">(United States, Nevada, Las Vegas), DelveInsight&rsquo;s&ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/botulism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Botulism &#8211; Pipeline Insight, 2023<\/a><\/strong>&rdquo; report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Botulism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/botulism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Botulism Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Over 4+ companies and 5+ pipeline drugs in Botulism are in various stages of development, and their anticipated acceptance in the Botulism market would significantly increase market revenue.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Botulism companies developing novel drug candidates to improve the Botulism treatment landscape include&nbsp; XOMA, CytoDel, AlphaVax,&nbsp; PanThera Biopharma, and others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Botulism pipeline therapies in various stages of development include Biodefence vaccines, NTM-1633, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Botulism Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Botulism is a rare, naturally occurring disease that is caused by botulinum toxins from bacteria called Clostridium botulinum. It is transmitted through food, contact with contaminated soil, or through an open wound. The symptoms of Botulism include constipation, drooping eyelids, paralysis, difficulty swallowing or speaking, facial weakness on both sides of the face, blurred vision, trouble breathing, nausea, vomiting, and abdominal cramps (only in foodborne botulism). A diagnosis of Botulism is made based on a thorough physical examination, a detailed patient history, and a variety of specialized tests. The standard test is a brain scan, cerebrospinal fluid examination, electromyography, and\/or edrophonium chloride test for myasthenia gravis. Early diagnosis of foodborne or wound botulism can be cured with antitoxin. The antitoxin attaches itself to a toxin that&#8217;s still circulating in the bloodstream. In infants, a treatment known as botulism immune globulin blocks the actions of neurotoxins circulating in the blood. If the infection results from a wound, the wound needs to be treated surgically.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Botulism Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Biodefence vaccines: AlphaVax<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">AlphaVax is developing immunostimulants as biodefence vaccines using Alphavaccine Platform System. The system is genetically derived from a modified alphavirus. The re-engineered alpha vaccine particles express the substituted gene (or genes), rather than producing more virus particles, thereby transforming the original virus into a highly effective vaccine system. Alphavaccines is currently in preclinical development for the treatment of botulism.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Discover more about the emerging Botulism drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/botulism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Botulism Treatment Drugs<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Botulism Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Biodefence vaccines: AlphaVax<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NTM-1633: XOMA<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Botulism Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s Report covers around 5+ products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Botulism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravitreal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subretinal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Molecule Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Product Type<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Drugs have been categorized under various product types like Mono, Combination, and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Botulism Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Botulism&nbsp; Companies: &nbsp;XOMA, CytoDel, AlphaVax, PanThera Biopharma, and others<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Botulism Pipeline Therapies: Biodefence vaccines, NTM-1633, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Find out more about the Botulism&nbsp; treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/botulism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Botulism Clinical Trials<\/a><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>1. <\/strong>Botulism Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Botulism Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Botulism Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Botulism Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Botulism Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Botulism Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Botulism Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Botulism Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.&nbsp; Botulism Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Botulism Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Botulism Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Botulism Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Botulism Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. BotulismMarket Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=botulism-pipeline-clinical-trials-and-key-companiescompanies-xoma-cytodel-alphavax-panthera-biopharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=botulism-pipeline-clinical-trials-and-key-companiescompanies-xoma-cytodel-alphavax-panthera-biopharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP (United States, Nevada, Las Vegas), DelveInsight\u2019s\u201cBotulism &#8211; Pipeline Insight, 2023\u201d report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Botulism pipeline landscape. (United States, Nevada, Las Vegas), DelveInsight&rsquo;s&ldquo;Botulism &#8211; Pipeline Insight, 2023&rdquo; &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/botulism-pipeline-clinical-trials-and-key-companiescompanies-xoma-cytodel-alphavax-panthera-biopharma_655133.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-655133","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=655133"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=655133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=655133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=655133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}